Introduction
In AML, the karyotype of the leukaemic blasts is the strongest prognostic factor for disease response and survival. A complex karyotype-AML (CK-AML), as defined by X3 chromosome abnormalities in the absence of t(8;21), inv (16) , t(16;16) and t (15;17) , has been associated with poor outcome in virtually all studies.
1-3 CR rates o50%, and a 2-year OS rates of 3-20% were reported. Due to a significant survival benefit in comparison with the conventional chemotherapy, allogeneic haematopoietic SCT (HSCT) using matched related-or unrelated-donors is the recommended treatment in CK-AML and other unfavourable karyotypes. [4] [5] [6] [7] However, even after standard related HSCT in CR1, unfavourable cytogenetics at diagnosis predicted an inferior outcome. 8, 9 In contrast, cytogenetics had less influence after HSCT from matched unrelated donors, arguing for a stronger GvL effect in the unrelated setting. 10 Similarly, comparable results among different cytogenetic subgroups have been observed by our group, using a sequential preparative regimen of conventional cytoreductive chemotherapy and reduced intensity conditioning (RIC) for HSCT in high-risk AML and myelodysplastic syndrome. 11 The protocol comprised of an intensive course of chemotherapy (fludarabine, AraC and amsacrine, FLAMSA), followed 3 days later by 4 Gy TBI and CY (FLAMSA-RIC). In a subsequent study in refractory AML, a lower number of chemotherapy courses given before FLAMSA-RIC was associated with superior outcome. 12 On the basis of these observations, we sought to improve the outcome of patients with CK-AML by employing the FLAMSA-RIC regimen for HSCT, as early as possible in the course of the disease.
Patients and methods
Among other experimental modifications, the German AML Cooperative Group (AML-CG) 2000 protocol (NCT00266136, clinicaltrials.gov) compared a standard double induction regimen of one course of thioguanine, standard-dose AraC as continuous infusion and DNR (TAD) followed by one course of high-dose AraC and mitoxanthrone (HAM) to the experimental arm, consisting of two courses of HAM, for first-line treatment in adult AML. 13 In 2004, the protocol was amended by a prospective pilot study for patients with CK-AML, investigating the feasibility and efficacy of early HSCT in these patients.
After primary diagnosis, patients with CK-AML received induction chemotherapy according to the main AML-CG 2000 protocol. Patients who were presented to the AML-CG transplant centres by external hospitals not using the AML-CG protocol were also accepted for the study, if presentation occurred during the first days after diagnosis, and if double induction was the planned strategy. In parallel to induction therapy, an urgent search for a related or unrelated stem cell donor was initiated. HLA-identical siblings or unrelated donors with a maximum of one allele-or Ag-mismatch were both considered acceptable for stem cell donation, as recent studies had shown comparable results after related and unrelated HSCT in high-risk AML. 10, 14 As soon as a donor was identified, no further induction course was given, and patients switched from the main study into the pilot trial for early HSCT. Beside a complex karyotype and an identified donor, inclusion criteria were: age from 18 to 60 years, absence of major organ dysfunctions and written informed consent. As per protocol, preparation for HSCT was started as soon as possible. Given the low response rate of CK-AML to conventional chemotherapy, preparation for HSCT was to be initiated also in patients with persistent leukaemia after one or two induction courses.
The FLAMSA-RIC preparative regimen for HSCT in high-risk AML and myelodysplastic syndrome has been described previously 11 In brief, patients received fludarabine (30 mg/m 2 ), high-dose AraC (2 g/m 2 ) and amsacrine (100 mg/m 2 ), each drug given from day À12 to À9 (FLAMSA regimen). Following 3 days of rest, 4 Gy TBI on day À5, CY (40 mg/kg for sibling donor transplants, 60 mg/kg for unrelated or mismatched donor transplants) on day À4 and À3, and rabbit anti-thymocyte globulin (10 mg/kg for sibling donor transplants, 20 mg/kg for unrelated or mismatched donor transplants) from day À4 until day À2 was given. For transplantation, G-CSF mobilised PBSCs were used. GvHD prophylaxis consisted of CyA starting on day -1, and mycophenolate mofetil (2 Â 15 mg/kg), given from day 0. In the absence of GvHD, mycophenolate mofetil was discontinued by day þ 50; CyA was tapered from day þ 60 and discontinued by day þ 90. Infection prophylaxis was used according to local standards. After HSCT, patients in remission qualified for prophylactic transfusion of donor lymphocytes (pDLT) at day þ 120 or later, if (1) there was no history of acute GvHD (aGvHD) 4III1, (2) immunosuppressive medication had been discontinued 430 days ago, without development of aGvHD, and (3) patients were free of infections. Up to three transfusions at 4-6 weeks' intervals were scheduled, using an escalating dose regimen. Cell doses for pDLT 1, 2 and 3 were 1 Â 
Evaluations and definitions
Disease response, 5 comorbidities 15 and GvHD 16 were classified as recommended. Date of neutrophil engraftment was defined as the first of two consecutive days with a peripheral blood (PB) neutrophil count 4500/mL. Date of platelet engraftment was defined as the first of three days with a platelet count 420 G/L without transfusion. At day þ 30, disease response and chimerism were assessed in PB and BM. As thrombocyte regeneration could be postponed by factors other than leukaemia and cytotoxic therapy (that is, GvHD, drugs or virus), CR after transplantation was defined by o5% blasts without evidence of dysplasia in BM and 41500 neutrophils/mL in PB. Relapse was defined by reappearance of blasts in PB, by any leukaemic infiltration outside the hematopoietic system, or by BM infiltration of 45% blasts. Non-relapse mortality (NRM) was defined as death from any reason in the absence of leukaemia.
Cytogenetic analysis
Chromosome analysis was performed using short-term cultures, following standard protocols. 17 The chromosomes were interpreted according to the International System for Human Cytogenetic Nomenclature (ISCN, Basel, Switzerland, 2009). 
Statistics
Results were analysed as of 19 January 2010. Feasibility of early transplant in CK-AML was the primary endpoint. OS from HSCT was the secondary endpoint; it was calculated from day of transplant to day of death or last follow-up. Leukaemia free survival (LFS) was calculated from day of transplant to day of either relapse or death in remission.
Cumulative incidences of relapse and of NRM were simultaneously calculated, accounting for competing risks. OS and LFS were estimated using the Kaplan-Meier method. Log-rank test was used for analysis of risk factors for time-to-event variables. R (R Project for Statistical Computing, URL http://www.R-project.org) and SPSS Version 18 (SPSS, Chicago, IL, USA) software were used for data analysis.
Study conduct
The protocol was approved by the ethics committee of the Ludwig-Maximilians University of Munich and was initiated by four centres. The study was performed according to the modified declaration of Helsinki; written informed consent was obtained from all patients.
Results
A total of 18 patients with CK-AML (10 de novo, five sAML and three tAML) were included between April 2005 and August 2007. Three centres took part in the study during the entire recruiting period; in these centres, 17/20 patients o60 years with CK-AML could be included after identification of a suitable donor, whereas one patient died during induction treatment, and for two patients, no suitable donor could be identified. Patients' characteristics are summarised in Table 1 and presented in detail in Table 2 . Median age was 53 (range: 20-63) years. Eight patients had achieved o5% blasts in BM after a single or double induction. Only one fulfilled the criteria of CR, seven had achieved CR with incomplete recovery of PB cell counts (CRi). Ten patients had active disease at start of FLAMSA-RIC after one (n ¼ 5) or two (n ¼ 5) induction courses. Median time from diagnosis to start of FLAMSA-RIC was 80 days. All patients were given PBSCs from HLA-identical sibling donors (n ¼ 7), matched unrelated donors (n ¼ 8) or a one-Ag mismatched donor (n ¼ 3), containing a median of 7.7 (range: 4.3-18.3) Â 10 6 CD34 þ cells/kg. Time to neutrophil and platelet engraftment was 18 (range: 10-33) and 16 (range: 11-64) days, respectively. After HSCT, one patient died in aplasia, one had persistent disease and 16 achieved CR with a median BM-donor chimerism 498% by day þ 30. Two patients relapsed during the first months after HSCT and died from progressive disease, one patient relapsing after 42 months could be salvaged by a second SCT from a haploidentical donor. Three patients died in remission from infections and/or GvHD, the cumulative incidence of relapse and NRM was 0.222 ± 0.098 and 0.235 ± 0.104, respectively ( Figure 2 ).
In all, 13 patients developed aGvHD of grade I (n ¼ 7), grade II (n ¼ 5) and grade IV (n ¼ 1). Median onset of aGvHD was day þ 22 (range: þ 11 to þ 30), the cumulative incidence was 0.765 ± 0.1029 for all stages of aGvHD and 0.367±0.120 for aGvHD Xstage II. Chronic GvHD (cGvHD) was observed in seven patients (47% of patients at risk; de novo, n ¼ 2, secondary to aGvHD, n ¼ 5), of which only two had extensive disease. The cumulative incidence was 0.481±0.123.
Eight patients qualified for pDLT after HSCT from a family (n ¼ 5) or an unrelated (n ¼ 3) donor. A history of severe aGVHD (n ¼ 2), ongoing or recently resolved cGvHD (n ¼ 6), progressive leukaemia and early death (n ¼ 1 each) were reasons to not give pDLT. Median time from HSCT to pDLT1 was 159 days; prolonged need for immunosuppressive medication was the main reason for Early allogeneic transplantation for complex karyotype AML C Schmid et al This patient received oral busulfan (8 Â 1 mg/kg q6 h) instead of 4 Gy TBI, due to his history of cns radiation for oligodendroglioma.
delay. As per protocol, six patients received three transfusions at 4 to 6 week intervals, following an escalating dose schedule, as described above. In two patients, pDLT was stopped after two transfusions because of relapse (n ¼ 1) or development of aGvHD (n ¼ 1). Furthermore, two patients developed limited cGvHD following the last pDLT; no GvHD was seen in five cases. After a median follow-up of 51 months, 11 patients are alive and in CR. OS and LFS at 4 years from SCT are 61 and 54%, respectively ( Figure 3 ). All patients transplanted in CR/CRi achieved long-term diseasefree survival, as compared with three out of ten patients with active disease at the time of HSCT (P ¼ 0.01). In contrast, patient age, patient and donor sex, time from diagnosis to transplantation, number of chemotherapy courses given before HSCT, de novo versus secondary disease and the HCT-comorbidity index 15 were not associated with OS. Outcome was superior in patients transplanted from an HLA-identical sibling donor as compared with a matched unrelated donor (P ¼ 0.01); however, this was because of a higher number of related donor transplants performed in CR (P ¼ 0.002 for the interaction).
Discussion
CK-AML represent a rather small subgroup, constituting 10-12% of all patients and 6-8% of patients o60 years. 19, 20 Allogeneic HSCT is the recommended treatment for CK-AML and other subgroups with unfavourable cytogenetics, although data from prospective trials are scarce. To our knowledge, this is the first study investigating an HSCT approach, exclusively dedicated to patients with CK-AML.
The strategy was based on the poor results of CK-AML after conventional treatment, usually resulting in low CR rates, early relapse and short OS. Hence, we studied the concept of immediate urgent donor search and allogeneic HSCT, performed as early as possible, and regardless of response to induction chemotherapy. As per protocol, induction treatment was interrupted, as soon as a suitable donor had been identified, to avoid futile or only shortterm effective treatment courses with potential toxicity. Instead, the relatively intensive FLAMSA chemotherapy was intended to serve as a platform for a GvL reaction, established by RIC-HSCT following immediately. Furthermore, the concept included a shift of the allogeneic immune reaction from the early to the intermediate post-transplant period: whereas the role of the GvL effect early after HSCT is not well established, severe aGvHD substantially contributes to NRM. In contrast, an allogeneic immune reaction against the leukaemia occurring later after HSCT might be of great value, as shown by the decreased relapse incidence in patients with cGvHD. 21 Similarly, donor cell transfusion for AML relapse after HSCT was ineffective against active disease, but more powerful if the disease was controlled by prior chemotherapy. 22 Therefore, antithymocyte globulin was applied, both for related and unrelated transplants, to control for aGvHD and to allow the patients to proceed to pDLT, given to augment the GvL effect once tolerance has been established.
The concept of early transplant was generally feasible. Within the three centres that were including patients during the entire recruiting period, 17 out of 20 patients o60 years, who presented with a CK-AML could be included after identification of a suitable donor. Further, the urgent donor search led to a start of conditioning o4 months from diagnosis in all, but three patients. In a similar approach, the Dresden Group investigated RIC-HSCT performed in aplasia after induction chemotherapy for high-risk AML. 23 In their study, an impressively short median interval of 40 days between diagnosis and transplantation was achieved by an urgent donor search programme of DKMS (the German bone marrow donor registry), one of the largest stem cell Early allogeneic transplantation for complex karyotype AML C Schmid et al donor registries worldwide. However, it took almost 7 years to include 26 high-risk patients. Nevertheless, like our results, their promising data support the strategy of early HSCT in high-risk disease and point out the feasibility of achieving early HSCT by an optimised donor search.
In our study, the toxicity of early FLAMSA-RIC was acceptable. No patient died after HSCT in CR/CRi, whereas four patients with active leukaemia at HSCT succumbed from treatment-related causes. This corresponds to published results, demonstrating an increased NRM in advanced or uncontrolled disease. 24 The concept of a delayed GvL reaction seemed to work as well, as shown by the low incidence of both severe aGvHD and early relapse, and by the fact that eight patients (50% of those achieving CR after HSCT) were able to receive pDLT. Under the conditions applied, pDLT was safe, even in the unrelated setting, causing mild GvHD in three out of eight patients. Only one patient could not complete the schedule of three transfusions because of aGvHD. Relapse occurred in two out of eight pDLT recipients. Although these data are encouraging, the small numbers obviously impede definitive conclusions on the efficacy of pDLT.
With respect to outcome, the results of this pilot study compare favourably with published data in patients with poor-risk karyotype AML. 5 The high cytogenetic complexity (with 15 out of 18 patients also fulfilling the definition of a monosomal karyotype) 25 , as well as the considerable comorbidity of our patients (Tables 1 and 2 ) argue against a selection bias in this cohort. A median follow-up of 44 years indicates sufficient maturity of the observed outcome data, although late relapses may happen, as seen in one patient. OS was 100% for patients transplanted in CR/CRi, supporting immediate HSCT, once control of the leukaemia has been achieved. Patients who achieved CRi after a second course of chemotherapy achieved a better outcome than patients transplanted with persistent disease. Hence, a second attempt to induce remission might be justified even in CK-AML.
The interpretation of our data may be hampered by the low number of patients. However, as stated above, CK-AML represents a clinically relevant, but small subgroup among younger AML patients, and most investigators do not report the number of patients with CK-AML separately, but within the unfavourable cohort. 9, 26 As an example, in a US-wide intergroup trial recruiting 609 patients o56 years over 5 years, only 63 patients with CK-AML were identified, and only 11 patients with unfavourable cytogenetics including CK-AML, received an allo-HSCT. 1 Hence, low numbers are an expected consequence in a prospective transplant study focussing on this particular subgroup, and a number of 18 patients included during 28 months seem to represent a realistic order of magnitude. Nevertheless, the results should best be confirmed by a larger prospective trial.
Conclusion
As targeted therapies for complex cytogenetic aberrations will not be feasible within the near future, approaches such as the strategy described here may be the most appropriate treatment for patients with CK-AML. Longterm survival can be achieved by early HSCT, in particular in CR/CRi. Further prospective studies in genetically defined AML subgroups should be encouraged to improve overall results.
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